The expansion is supported by the FDA’s analysis of additional data from two randomised, controlled clinical trials that included patients with mild or moderate disease.
The European Commission (EC) has provided conditional marketing authorisation for Gilead Sciences to use Veklury (remdesivir) for the treatment of Covid-19.